Publikasi Scopus 2024 per tanggal 29 Februari 2024 (130 artikel)

Supali T.; Djuardi Y.; Santoso; Sianipar L.R.; Suryaningtyas N.H.; Alfian R.; Destani Y.; Iskandar E.; Astuty H.; Sugianto N.; Fischer P.U.
Supali, Taniawati (6602742029); Djuardi, Yenny (6507800820); Santoso (57221334416); Sianipar, Lita Renata (57212562534); Suryaningtyas, Nungki Hapsari (57221330832); Alfian, Rahmat (57222748640); Destani, Yossi (57222743128); Iskandar, Elisa (57202299885); Astuty, Hendri (57193240808); Sugianto, Noviani (57216629981); Fischer, Peter U. (23567680200)
6602742029; 6507800820; 57221334416; 57212562534; 57221330832; 57222748640; 57222743128; 57202299885; 57193240808; 57216629981; 23567680200
Surveillance and Selective Treatment of Brugia malayi Filariasis Eleven Years after Stopping Mass Drug Administration in Belitung District, Indonesia
2024
American Journal of Tropical Medicine and Hygiene
110
1
111
116
5
Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Baturaja Unit for Health Research and Development, National Institute of Health Research and Development, Ministry of Health of Indonesia, South Sumatra, Indonesia; Directorate of Communicable Disease, Prevention, and Control, Indonesia Ministry of Health, Jakarta, Indonesia; Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States; Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Salemba 6, Jakarta, 10430, Indonesia
Supali T., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Salemba 6, Jakarta, 10430, Indonesia; Djuardi Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Santoso, Baturaja Unit for Health Research and Development, National Institute of Health Research and Development, Ministry of Health of Indonesia, South Sumatra, Indonesia; Sianipar L.R., Directorate of Communicable Disease, Prevention, and Control, Indonesia Ministry of Health, Jakarta, Indonesia; Suryaningtyas N.H., Baturaja Unit for Health Research and Development, National Institute of Health Research and Development, Ministry of Health of Indonesia, South Sumatra, Indonesia; Alfian R., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Destani Y., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Iskandar E., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Astuty H., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Sugianto N., Department of Parasitology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Fischer P.U., Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO, United States
Brugia malayi is the major cause of lymphatic filariasis (LF) in Indonesia. Zoophilic B. malayi was endemic in Belitung district, and mass drug administration (MDA) with diethylcarbamazine (DEC) and albendazole ceased after five annual rounds in 2010. The district passed three transmission assessment surveys (TAS) between 2011 and 2016. As part of the post-TAS3 surveillance of the national LF elimination program, we collected night blood samples for microfilaria (Mf) detection from 1,911 subjects more than 5 years of age in seven villages. A B. malayi Mf prevalence ranging from 1.7% to 5.9% was detected in five villages. Only 2 (5%) of the total 40 Mf-positive subjects were adolescents aged 18 and 19 years old, and 38 (95%) Mf-positive subjects were 21 years and older. Microfilarial densities in infected individuals were mostly low, with 60% of the subjects having Mf densities between 16 and 160 Mf/mL. Triple-drug treatment with ivermectin, DEC, and albendazole (IDA) was given to 36 eligible Mf-positive subjects. Adverse events were mostly mild, and treatment was well tolerated. One year later, 35 of the treated Mf-positive subjects were reexamined, and 33 (94%) had cleared all Mf, while the anti-Bm14 antibody prevalence remained almost unchanged. Results indicate that in B. malayi-endemic areas, post-TAS3 surveillance for Mf in the community may be needed to detect a potential parasite reservoir in adults. Selective treatment with IDA is highly effective in clearing B. malayi Mf and should be used to increase the prospects for LF elimination if MDA is reintroduced. Copyright © 2024 The author(s)
albendazole; antigen; Bm14 antigen; diethylcarbamazine; immunoglobulin antibody; immunoglobulin G4 antibody; ivermectin; unclassified drug; adult; age; arthralgia; Article; blood sampling; blood smear; Brugia malayi; Brugian filariasis; child; combination chemotherapy; controlled study; density; disease elimination; disease reservoir; drug safety; drug tolerability; endemic disease; female; fever; follow up; headache; health survey; human; hypertension; Indonesia; major clinical study; male; Microfilaria; microfilarial density; microfilariasis; microscopy; myalgia; nausea; nonhuman; optical density; preschool child; prevalence; school child; sex difference; treatment duration; village; vomiting
Bill and Melinda Gates Foundation, BMGF
Financial support: This study was supported by grant no. INV-031336 from the Bill & Melinda Gates Foundation to Washington University.
American Society of Tropical Medicine and Hygiene
00029637
38011734
Article
Q1
1042
3942